Want to hear from ISMP about how you can get more value from your internal medication error and adverse event reporting program? Attend a free international webinar on September 15, 2020, from 7:00-8:00 am ET to find out how healthcare organizations worldwide can better gather key information, analyze error data, and identify medication safety risks. For more information or to register: https://ismp.org/events/enhancing-your-medication-error-reporting-progra...
MSOS News
Sign up now for the next MSOS Member Briefing webinar scheduled to be held on Thursday, July 23, 2020 from 1:00-2:00 PM ET.
Register Now: https://ecri.zoom.us/webinar/register/WN_qKo3g7JkT3KgblfLClqEOw
Short medication safety-related presentations for this webinar will include:
• Eliminating Inadvertent Exposure with Patient Specific Scanning of Multi-Use Medications
Steve Mogridge PA-C, Medication Safety Manager, Spectrum Health
Megan Fletcher PharmD, Director of Pharmacy, Spectrum Health
• The Medication Safety Minute
Eileen Relihan PhD (Pharm), MSc.(Hosp Pharm), BSc.(Pharm), Dip LQH, MPSI, Medication Safety Facilitator, St. James’s Hospital Dublin, Ireland
•Pharmacy & Anesthesia: A Match Made in Medication Standardization and Safety Heaven
Jameika M. Stuckey PharmD, BCACP Medication Safety Manager University of Mississippi Medical Center
ISMP has received multiple reports recently about fentaNYL patches being inappropriately prescribed for opioid-naïve, elderly patients upon discharge from a hospital and transfer to a long-term care facility. This week’s ISMP newsletter featured article presents recommendations for system safeguards to avoid the risk of patient harm. For more, see: https://ismp.org/node/18707
Due to the COVID-19 pandemic, our survey on the level of implementation of the two new 2020-2021 Targeted Medication Safety Best Practices (TMSBPs) for Hospitals was put on hold. As crisis mode begins to diminish, we would appreciate your participation in this survey regardless of whether you have implemented the Best Practices.. The survey is available at: www.ismp.org/ext/350 and will be open through July 17, 2020. Since we are only conducting the survey on the two new Best Practices, it should only take you about 5 minutes to complete. You can view all the TMSBPs by going to: www.ismp.org/node/160
Due to shortages of neuromuscular blocking agents needed for critically ill COVID-19 patients, the FDA has allowed temporary manufacture of these drugs without the usual statement: “Warning: Paralyzing Agent” on the vial cap. The lack of a warning statement may make vials look similar to other medications and lead to possible confusion and errors. For ISMP recommendations to avoid mix-ups and ensure safe storage, visit: https://ismp.org/node/18346
